Cyclohexanols

Publication Title: 
Obstetrics and Gynecology

OBJECTIVE: To describe the effects of six interventions for menopausal vasomotor symptoms relative to control in a pooled analysis, facilitating translation of the results for clinicians and symptomatic women. The Menopause Strategies: Finding Lasting Answers for Symptoms and Health network tested these interventions in three randomized clinical trials. METHODS: An analysis of pooled individual-level data from three randomized clinical trials is presented. Participants were 899 perimenopausal and postmenopausal women with at least 14 bothersome vasomotor symptoms per week.

Author(s): 
Guthrie, Katherine A.
LaCroix, Andrea Z.
Ensrud, Kristine E.
Joffe, Hadine
Newton, Katherine M.
Reed, Susan D.
Caan, Bette
Carpenter, Janet S.
Cohen, Lee S.
Freeman, Ellen W.
Larson, Joseph C.
Manson, JoAnn E.
Rexrode, Kathy
Skaar, Todd C.
Sternfeld, Barbara
Anderson, Garnet L.
Publication Title: 
The Cochrane Database of Systematic Reviews

BACKGROUND: This is an updated version of the Cochrane review published in 2005 on selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headache. The original review has been split in two parts and this review now only regards tension-type headache prevention. Another updated review covers migraine. Tension-type headache is the second most common disorder worldwide and has high social and economic relevance.

Author(s): 
Banzi, Rita
Cusi, Cristina
Randazzo, Concetta
Sterzi, Roberto
Tedesco, Dario
Moja, Lorenzo
Publication Title: 
Acta Psychiatrica Scandinavica

OBJECTIVE: To describe a never previously reported case of erotomania induced by venlafaxine and highlight the effect of antidepressants on the dopaminergic system. METHOD: A case of erotomania is described. RESULT: Erotomania occurring in two separate occasions developed after treatment with high doses of venlafaxine. The episode remitted only after lowering the dose of the venlafaxine. CONCLUSION: Erotomania may occur with agents such as antidepressants. The dopamine neurotransmission of mood can provide further evidence for the development of newer classes of antidepressants.

Author(s): 
Adamou, M.
Hale, A. S.
Publication Title: 
Der Anaesthesist

Tramadol-HCl was used clinically in the form of a continuous infusion as the analgesic component of a balanced anaesthetic technique. In over 90% of the anaesthetics a further injection of barbiturate and/or supplementary muscle relaxant was necessary because the patients did not tolerate the operative procedure.

Author(s): 
Rothhammer, A.
Weis, K. H.
Skrobek, W.
Publication Title: 
European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology

The ?-phenylethylamines are known to act as ligands for the trace amine receptors, a novel family of G-protein-coupled receptors. The trace amines are stored and released along with various neurotransmitter agents such as norepinephrine, serotonin, and dopamine and thus work as neuromodulator or neurotransmitter agents. Trace amines are known to play an important role in the pathophysiology of major depression.

Author(s): 
Dhir, Ashish
Malik, Sneh
Kessar, S. V.
Singh, K. N.
Kulkarni, S. K.
Publication Title: 
Chemical Senses

Scientific research on the effects of essential oils on human behavior lags behind the promises made by popular aromatherapy. Nearly all aspects of human behavior are closely linked to processes of attention, the basic level being that of alertness, which ranges from sleep to wakefulness. In our study we measured the influence of essential oils and components of essential oils [peppermint, jasmine, ylang-ylang, 1,8-cineole (in two different dosages) and menthol] on this core attentional function, which can be experimentally defined as speed of information processing.

Author(s): 
Ilmberger, J.
Heuberger, E.
Mahrhofer, C.
Dessovic, H.
Kowarik, D.
Buchbauer, G.
Publication Title: 
Menopause (New York, N.Y.)

OBJECTIVE: This report describes the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health network and methodological issues addressed in designing and implementing vasomotor symptom trials. METHODS: Established in response to a National Institutes of Health request for applications, the network was charged with conducting rapid throughput randomized trials of novel and understudied available interventions postulated to alleviate vasomotor and other menopausal symptoms.

Author(s): 
Newton, Katherine M.
Carpenter, Janet S.
Guthrie, Katherine A.
Anderson, Garnet L.
Caan, Bette
Cohen, Lee S.
Ensrud, Kristine E.
Freeman, Ellen W.
Joffe, Hadine
Sternfeld, Barbara
Reed, Susan D.
Sherman, Sheryl
Sammel, Mary D.
Kroenke, Kurt
Larson, Joseph C.
LaCroix, Andrea Z.
Publication Title: 
Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology

OBJECTIVE: To assess whether pretreatment theta current density in the rostral anterior cingulate (rACC) and medial orbitofrontal cortex (mOFC) differentiates responders from non-responders to antidepressant medication or placebo in a double-blinded study. METHODS: Pretreatment EEGs were collected from 72 subjects with Major Depressive Disorder (MDD) who participated in one of three placebo-controlled trials. Subjects were randomized to receive treatment with fluoxetine, venlafaxine, or placebo.

Author(s): 
Korb, Alexander S.
Hunter, Aimee M.
Cook, Ian A.
Leuchter, Andrew F.
Publication Title: 
Journal of Psychiatric Research

Individuals with Major Depressive Disorder (MDD) vary regarding the rate, magnitude and stability of symptom changes during antidepressant treatment. Growth mixture modeling (GMM) can be used to identify patterns of change in symptom severity over time. Quantitative electroencephalographic (QEEG) cordance within the first week of treatment has been associated with endpoint clinical outcomes but has not been examined in relation to patterns of symptom change.

Author(s): 
Hunter, Aimee M.
Muthén, Bengt O.
Cook, Ian A.
Leuchter, Andrew F.
Publication Title: 
Psychiatry Research

In treatment trials for major depressive disorder (MDD), early symptom improvement is predictive of eventual clinical response. Clinical response may also be predicted by elevated pretreatment theta (4-7Hz) current density in the rostral anterior cingulate (rACC) and medial orbitofrontal cortex (mOFC). We investigated the relationship between pretreatment EEG and early improvement in predicting clinical outcome in 72 MDD subjects across three placebo-controlled treatment trials. Subjects were randomized to receive fluoxetine, venlafaxine, or placebo.

Author(s): 
Korb, Alexander S.
Hunter, Aimee M.
Cook, Ian A.
Leuchter, Andrew F.

Pages

Subscribe to RSS - Cyclohexanols